Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development of olpasiran, a first-in-class, synthetic, double-stranded, N-acetylgalactosamine-conjugated small interfering RNA (siRNA) designed to directly inhibit LPA messenger RNA translation in hepatocytes and potently reduce plasma Lp(a) concentration. Olpasiran reduced Lp(a) concentrations in transgenic mice and cynomolgus monkeys in a dose-responsive manner, achieving up to over 80% reduction from baseline for 5-8 weeks after administration of a single dose. In a phase 1 dose-escalation trial of olpasiran (ClinicalTrials.gov: NCT03626662 ), the primary outcome was safety and tolerability, and the secondary outcomes were the change in Lp(a) concentrations and olpasiran pharmacokinetic parameters. Participants tolerated single doses of olpasiran well and experienced a 71-97% reduction in Lp(a) concentration with effects persisting for several months after administration of doses of 9 mg or higher. Serum concentrations of olpasiran increased approximately dose proportionally. Collectively, these results validate the approach of using hepatocyte-targeted siRNA to potently lower Lp(a) in individuals with elevated plasma Lp(a) concentration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase 1 trial of 64 patients, olpasiran reduced Lp(a) by − 71% to − 97% [213].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [213]
In the citing paper
“In pre-clinical studies olpasiran successfully reduced Lp(a) levels in transgenic mice and cynomolgus monkeys [213].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [213]
Citations
Cites
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073
miRBase: from microRNA sequences to function
Kozomara, A., Birgaoanu, M., & Griffiths-Jones, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1141 · Cited by 4,843
miRBase: tools for microRNA genomics
Griffiths-Jones, S., Saini, H. K., van Dongen, S., & Enright, A. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm952 · Cited by 4,382
miRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634
GENCODE reference annotation for the human and mouse genomes
Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J. M., Sisu, C., Wright, J., Armstrong, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky955 · Cited by 3,040
Griffiths-Jones, S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh023 · Cited by 2,220
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citationGenetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Research works printed but not linked: 1
- Nugent, A., Gray, J., Gorby, L. & Moriarty, P. Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein (a). J. Clin. Cardiol. 1, 16–21 (2019).
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
“Reductions ranging between 71% and 97% were observed with olpasiran (formerly AMG 890), a N-acetylgalactosamine (GalNAc)-conjugated siRNA, which were sustained for over 6 months.(205) Both treatments showed a favourable safety profile.”
BackgroundSelf-citationSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
O’Donoghue, M. L., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knusel, B., Kuder, J. F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2211023 · Cited by 599
Self-citationLipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau, F., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 363
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Metadata
- Authors
- Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., Haldar, S. M., Sohn, W., Wang, H., Elliott-Davey, M., Rock, B. M., Pei, T., Homann, O., Hellawell, J., & Watts, G. F.
- Affiliations
- Jacksonville Center for Clinical Research (US)
- University of Kansas Medical Center (US)
- Orange County Research Center (US)
- NYU Langone Health (US)
- Amgen (United States) (US)
- Arrowhead Pharmaceuticals (United States) (US)
- The University of Western Australia (AU)
- Corresponding author
- Koren, Michael J.
- ORCID
- Venue
- Nature Medicine
- Published
- 2022-01
- Volume
- 28
- Issue
- 1
- Pages
- 96-103
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4206591430
- Semantic Scholar
- 67f8e9c86c185a0a30900c9544ebad034ae5ed66
- Cited by
- 239
- References
- 49
- Citations by year
- 2026: 26 · 2025: 41 · 2024: 49 · 2023: 70 · 2022: 53
- FWCI
- 50.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- 社会経済史学
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- olpasiran, lipoprotein(a), siRNA therapeutics, cardiovascular disease, coronary artery disease, Lp(a) lowering, pharmacokinetics, safety and tolerability, preclinical models
- MeSH terms
- Adult, Animals, Female, Humans, Hyperlipidemias, Macaca fascicularis, Male, Mice, Transgenic, Middle Aged, Lipoprotein(a), RNA, Small Interfering, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). https://app.cochat.ai/papers/10.1038/s41591-021-01634-w
- The paper
- Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., Haldar, S. M., Sohn, W., Wang, H., Elliott-Davey, M., Rock, B. M., Pei, T., Homann, O., Hellawell, J., & Watts, G. F. (2022). Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nature Medicine. https://doi.org/10.1038/s41591-021-01634-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.